The concern of generic challenges has repeatedly loomed around copyright’s iconic drug, Sildenafil, raising questions about the outlook of connected pharmaceutical portfolios. While initial periods saw impressive profits, the patent end has created the path for cheaper substitutes, possibly lowering earnings and presenting a significant danger fo